Promis Neurosciences (PMN) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Promis Neurosciences (NASDAQ: PMN):

• 7/7/2026 – Promis Neurosciences is now covered by Roth Capital. They set a “buy” rating and a $19.00 price target on the stock.
• 6/30/2026 – Promis Neurosciences is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 6/24/2026 – Promis Neurosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 6/20/2026 – Promis Neurosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 6/11/2026 – Promis Neurosciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 6/9/2026 – Promis Neurosciences was upgraded by Zacks Research to “hold”.
• 6/8/2026 – Promis Neurosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $18.00 price target on the stock.
• 5/31/2026 – Promis Neurosciences was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/20/2026 – Promis Neurosciences was upgraded by Brookline Capital Markets to “strong-buy”.

Insider Transactions at Promis Neurosciences

In related news, Director Patrick D. Kirwin purchased 4,000 shares of Promis Neurosciences stock in a transaction on Wednesday, April 22nd. The stock was acquired at an average price of $11.33 per share, for a total transaction of $45,320.00. Following the completion of the transaction, the director directly owned 4,653 shares in the company, valued at $52,718.49. This represents a 612.56% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.